HepaTx is pleased to announce the recent issuance of a new patent by the Canadian Intellectual Property Office on August 22, 2023. The patent, titled “Methods and Compositions for Producing Hepatocyte-Like Cells,
Palo Alto, 9/26/2023 – HepaTx is pleased to announce the recent issuance of a new patent by the Canadian Intellectual Property Office on August 22, 2023. The patent, titled "Methods and Compositions for Producing Hepatocyte-Like Cells," adds to the company's growing portfolio of intellectual property and builds on the success of previously granted patents in the United States and Japan.
The patent titled “Methods and Composition for Producing Hepatocyte-Like Cells” covers the critical composition of matter claims for hepatocyte-like cells manufactured from adipose-derived stromal cells. HepaTx’s approach to developing an off-the-shelf cell therapy to treat patients with serious liver disease is unique in that HepaTx does not genetically modify its cells, it uses adipose tissue as a starting material and is scalable to meet expected future demand. Unlike other liver therapy companies, HepaTx’s novel technology does not rely on cadaver liver tissue donations.
The issuance of the Canadian patent (Canada Patent No. 2,959,117) follows closely on the heels of HepaTx's successful grants of patents in the United States (US Patent No. 11291691) and Japan (Japanese patent No. 7057797). These international patents highlight HepaTx's global reach and dedication to providing solutions for patients worldwide.
As HepaTx continues to expand its global presence, the company remains committed to improving the quality of life for patients with liver diseases and advancing the field of regenerative medicine. The new Canadian patent represents a significant step towards realizing these goals and marks another chapter in HepaTx's journey of innovation and excellence.
About HepaTx
HepaTx is a cell therapy and regenerative medicine company developing cell-based treatments for late-stage liver disease, a highly underserved and cost-intensive market. To learn more, visit our website, Hepatx.com, and follow us on Twitter, @hepatx, and LinkedIn.
Contact:
HepaTx
Claudia Preziosi
cpreziosi@hepatx.com